BBIQ
规格
| Cas Number | 1229024-57-0 |
| 规格或纯度 | ≥97% |
| 纯度 | ≥97% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 16.67 mg/mL (50.45 mM; ultrasonic and warming and heat to 60°C) |
| 过滤标签 | Toll-like Receptor (TLR),Immunology/Inflammation |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | BBIQ 是一种咪唑喹啉化合物，是一种强效的选择性收费样受体 7（TLR7）激动剂，对人类 TLR7 的 EC 50 值为 u202f59.1u202fnM 。BBIQ 是一种强大的疫苗佐剂，可增强先天性免疫反应。 |
| 英文描述 |
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of 59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responses In Vitro BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 µg/mL). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In mice treated with Chloroquine (CQ) alone, parasite ( P. berghei ANKA) appearesd on Day 17 and all mice of this group died by Day 21. Whereas, mice treated with BBIQ along with CQ exhibits no appearance of parasite till Day 23. Frequencies of T cells (CD3+, CD4+and CD8+) and T regulatory cells (CD4+, CD25 +and FoxP3+) are lower in brain of BBIQ + CQ treated mice as compared to BBIQ alone and CQ alone treated mice on Day 10. Inhibition of infiltration of inflammatory T cells and activation of T helper and T cytotoxic cells against the parasite is observed in the mice treated with this combination therapy. Serum levels of IFN-γ and IL-12 are higher on same day in mice treated with BBIQ + CQ which reveals the generation of strong Th1 immune response in mice against the infection . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TLR7 59.1 nM (EC 50 , Human TLR7) |